TG Therapeutics EV/EBIT TGTX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.

Today, Oct 23, 2026: 62.2×
3-year median: 57.5×
Against its 3-year history: 61st; percentile: 0 is its lowest day, 100 its highest
3-year range: 32.4× to 161×
Peer median: 54.6×

TG Therapeutics' EV/EBIT is 62.2× as of Oct 23, 2026.

That is above its 3-year median of 57.5×, close to the middle of its last 3 years.

Over that time it ranged from 32.4× in Sep 2024 to 161× in May 2025.

The median for 10 large drugmakers of a similar size is 54.6×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	62.2×	37.0×	65.9×
2025	48.6×	48.6×	161×
2024	39.8×	32.4×	129×

Against its peers

Companies in Drug Manufacturers - General nearest TG Therapeutics' size, closest first, today.

Company	EV/EBIT
TGTXTG Therapeutics	62.2×
PTGXProtagonist Therapeutics	140×
CORTCorcept Therapeutics	n/m
ALKSAlkermes plc.	69.6×
AMRXAmneal Pharmaceuticals	18.3×
BMRNBiomarin Pharmaceutical	25.8×
LGNDLigand Pharmaceuticals	57.7×
KNSAKiniksa Pharmaceuticals International	54.6×
JAZZJazz Pharmaceuticals	15.9×
INDVIndivior Pharmaceuticals	7.8×
ARQTArcutis Biotherapeutics	111×
Peer median	54.6×

Where TG Therapeutics ranks

#44of 48Large drugmakers with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on TG Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.